65 related articles for article (PubMed ID: 10950800)
1. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia.
Nelson S; Heyder AM; Stone J; Bergeron MG; Daugherty S; Peterson G; Fotheringham N; Welch W; Milwee S; Root R
J Infect Dis; 2000 Sep; 182(3):970-3. PubMed ID: 10950800
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis.
Root RK; Lodato RF; Patrick W; Cade JF; Fotheringham N; Milwee S; Vincent JL; Torres A; Rello J; Nelson S;
Crit Care Med; 2003 Feb; 31(2):367-73. PubMed ID: 12576938
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia.
Hartmann P; Lammertink J; Mansmann G; Hübel K; Salzberger B; Stützer H; Engert A; Fätkenheuer G
Eur J Med Res; 2005 Jan; 10(1):29-35. PubMed ID: 15737951
[TBL] [Abstract][Full Text] [Related]
4. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
6. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
7. Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: A randomized, controlled trial.
Bauhofer A; Plaul U; Torossian A; Koller M; Stinner B; Celik I; Sitter H; Greger B; Middeke M; Schein M; Wyatt J; Nyström PO; Hartung T; Rothmund M; Lorenz W
Surgery; 2007 Apr; 141(4):501-10. PubMed ID: 17383527
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
9. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
10. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
11. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group.
Nelson S; Belknap SM; Carlson RW; Dale D; DeBoisblanc B; Farkas S; Fotheringham N; Ho H; Marrie T; Movahhed H; Root R; Wilson J
J Infect Dis; 1998 Oct; 178(4):1075-80. PubMed ID: 9806037
[TBL] [Abstract][Full Text] [Related]
13. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
[TBL] [Abstract][Full Text] [Related]
14. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.
Nathan RV; Rhew DC; Murray C; Bratzler DW; Houck PM; Weingarten SR
Am J Med; 2006 Jun; 119(6):512.e1-7. PubMed ID: 16750965
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM
Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia.
Carlsson G; Ahlin A; Dahllöf G; Elinder G; Henter JI; Palmblad J
Br J Haematol; 2004 Jul; 126(1):127-32. PubMed ID: 15198743
[TBL] [Abstract][Full Text] [Related]
17. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia.
deBoisblanc BP; Mason CM; Andresen J; Logan E; Bear MB; Johnson S; Shellito J; Summer WR; Nelson S
Respir Med; 1997 Aug; 91(7):387-94. PubMed ID: 9327037
[TBL] [Abstract][Full Text] [Related]
19. [Community-acquired pneumonia in hospitalized adult patients. Clinical presentation and prognostic factors].
Saldías F; Mardónez JM; Marchesse M; Viviani P; Farías G; Díaz A
Rev Med Chil; 2002 Dec; 130(12):1373-82. PubMed ID: 12611238
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
